Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -147.07% is 26% above its 5-year average of -199.69%, near the high end of its 5-year range (-944.86%–78.98%).
53.92% above its 12-month average of -319.17%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
-147.07%
EBITDA MARGIN AVG TTM
-319.17%
EBITDA MARGIN AVG 3Y
-354.30%
EBITDA MARGIN AVG 5Y
-199.69%
EBITDA MARGIN AVG 10Y
-262.84%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+53.92%
CURRENT VS 3Y AVG
+58.49%
CURRENT VS 5Y AVG
+26.35%
CURRENT VS 10Y AVG
+44.05%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Moderna, Inc.
Market Cap
$55.68B
EBITDA Margin
-147.07%
TTM Avg
-319.17%
3Y Avg
-354.30%
5Y Avg
-199.69%
Market Cap
$56.32B
EBITDA Margin
1.40%
TTM Avg
1.39%
3Y Avg
1.08%
5Y Avg
0.86%
Market Cap
$49.93B
EBITDA Margin
29.55%
TTM Avg
28.88%
3Y Avg
30.96%
5Y Avg
31.73%
Market Cap
$49.35B
EBITDA Margin
23.08%
TTM Avg
23.14%
3Y Avg
23.23%
5Y Avg
22.53%
Market Cap
$66.86B
EBITDA Margin
26.60%
TTM Avg
24.95%
3Y Avg
24.24%
5Y Avg
23.28%
Market Cap
$42.81B
EBITDA Margin
18.31%
TTM Avg
11.44%
3Y Avg
6.73%
5Y Avg
5.67%
Market Cap
$42.67B
EBITDA Margin
21.04%
TTM Avg
21.29%
3Y Avg
20.90%
5Y Avg
20.09%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | $55.68B | -147.07% | -319.17% | -354.30% | -199.69% |
| Cardinal Health, Inc. (CAH)vs › | $56.32B | 1.40% | 1.39% | 1.08% | 0.86% |
| Edwards Lifesciences Corporation (EW)vs › | $49.93B | 29.55% | 28.88% | 30.96% | 31.73% |
| Becton, Dickinson and Company (BDX)vs › | $49.35B | 23.08% | 23.14% | 23.23% | 22.53% |
| Humana Inc. (HUM)vs › | $48.40B | 1.76% | 1.98% | 3.17% | 4.08% |
| Cencora, Inc. (COR)vs › | $63.17B | 1.46% | 1.44% | 1.41% | 1.40% |
| Boston Scientific Corporation (BSX)vs › | $66.86B | 26.60% | 24.95% | 24.24% | 23.28% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.81B | 18.31% | 11.44% | 6.73% | 5.67% |
| IQVIA Holdings Inc. (IQV)vs › | $42.67B | 21.04% | 21.29% | 20.90% | 20.09% |
| Agilent Technologies, Inc. (A)vs › | $41.48B | 25.43% | 26.12% | 26.05% | 25.37% |
Gross Margin
55.4%
EBITDA Margin
-147.1%
Operating Margin
-158.1%
Net Margin
-141.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -518.62% |
| 2026-03-31 | -341.65% |
| 2025-12-31 | -116.52% |
| 2025-09-30 | -20.47% |
| 2025-06-30 | -598.59% |
| 2025-03-31 | -944.86% |
| 2024-12-31 | -124.06% |
| 2024-09-30 | -0.97% |
| 2024-06-30 | -598.19% |
| 2024-03-31 | -736.53% |
| 2023-12-31 | 7.39% |
| 2023-09-30 | -96.29% |
| 2023-06-30 | -516.57% |
| 2023-03-31 | -15.67% |
| 2022-12-31 | 32.24% |
| 2022-09-30 | 39.72% |
| 2022-06-30 | 55.26% |
| 2022-03-31 | 72.49% |
| 2021-12-31 | 78.98% |
| 2021-09-30 | 75.13% |
| 2021-06-30 | 74.28% |
| 2021-03-31 | 73.49% |
| 2020-12-31 | -46.84% |
| 2020-09-30 | -143.51% |
| 2020-06-30 | -172.61% |
| 2020-03-31 | -1471.13% |
| 2019-12-31 | -865.29% |
| 2019-09-30 | -724.50% |
| 2019-06-30 | -1041.20% |
| 2019-03-31 | -838.15% |
| 2018-12-31 | -411.28% |
| 2018-09-30 | -190.00% |
| 2018-06-30 | -315.89% |
| 2018-03-31 | -248.80% |
| 2017-12-31 | -39.08% |
| 2017-09-30 | -147.72% |
| 2017-06-30 | -210.18% |
| 2017-03-31 | -210.18% |
